Evidence map›Paper›PMID 34222668›Full record

ArticleOpen medicine (Warsaw, Poland)2021

lncRNA MALAT1 regulated ATAD2 to facilitate retinoblastoma progression via miR-655-3p.

Yuxin Zhao, Zhaoxia Wang, Meili Gao, Xuehong Wang, Hui Feng, Yuanyuan Cui, Xia Tian

Open access · goldAbstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Potential roles of lncRNA MALAT1-miRNA interactions in ocular diseases.Journal of cell communication and signaling · 2023
    Review
  3. Long non-coding RNAs involved in retinoblastoma.Journal of cancer research and clinical oncology · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yuxin ZhaoDepartment of Ophthalmology, Weihai Central Hospital, No. 3, Mishandongluxi, Wendeng District, Weihai, 264400, Shandong, China.
Zhaoxia WangDepartment of Pediatric, Weihai Central Hospital, Weihai, Shandong, China.
Meili GaoDepartment of Ophthalmology, Weihai Central Hospital, No. 3, Mishandongluxi, Wendeng District, Weihai, 264400, Shandong, China.
Xuehong WangDepartment of Ophthalmology, Weihai Central Hospital, No. 3, Mishandongluxi, Wendeng District, Weihai, 264400, Shandong, China.
Hui FengDepartment of Ophthalmology, Weihai Central Hospital, No. 3, Mishandongluxi, Wendeng District, Weihai, 264400, Shandong, China.
Yuanyuan CuiDepartment of Ophthalmology, Weihai Central Hospital, No. 3, Mishandongluxi, Wendeng District, Weihai, 264400, Shandong, China.
Xia TianDepartment of Ophthalmology, Weihai Central Hospital, No. 3, Mishandongluxi, Wendeng District, Weihai, 264400, Shandong, China.
Weihai Municipal Hospital · CNWeihai Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was reported as an oncogene in many tumors including retinoblastoma (RB). This research mainly focused on the functions and mechanism of MALAT1 in RB. MALAT1 was upregulated in RB tissues and cells, and it served as a competing endogenous RNA (ceRNA) and inhibited miRNA-655-3p (miR-655-3p) expression, which eventually regulated the expression of miR-655-3p downstream target ATPase Family AAA Domain Containing 2 (ATAD2). The level of ATAD2 significantly increased, while that of miR-655-3p remarkably decreased in RB tissues and cells. MALAT1 depletion inhibited cell proliferation, metastasis, and epithelial-mesenchymal transition (EMT), but promoted apoptosis

Indexed as

ATAD2MALAT1miR-655-3pretinoblastomatumor progression

Identifiers

PMID34222668
PMCPMC8231467
OpenAlexW3175929529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.